Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
BACKGROUND
Delayed onset of efficacy of antidepressants and a high proportion of depressed patients being poor or non-responders to antidepressants are well known clinical challenges. Therefore, it seems to be necessary to identify predictors for response and - even more important - for remission. It has been suggested that reduction of depressive symptoms at an early stage of antidepressant treatment may predict treatment outcome. Our objective was to test, if this hypothesis derived from randomized controlled studies (RCTs) in outpatients, would be confirmed in a large naturalistic study in a cohort of inpatients with major depression. Patients were treated with various antidepressants and co-medication according to the protocol based on evidence-based clinical guidelines.


METHODS
This was a large naturalistic prospective study. All patients (N=795) were hospitalized and met DSM-IV criteria for major depression according to a structured clinical interview (SCID). Assessments were conducted biweekly. Several definitions of early improvement (20%, 25% and 30% reduction in HAMD-21 baseline total scores) at two different visits were tested. Sensitivity, specificity and predictive values were calculated for the different definitions of early improvement. ROC-analyses as well as logistic regression models have been performed. Response was defined as 50% improvement of the total baseline HAMD-21 score and remission as a score of </=7 at discharge. Additionally, time to response was analyzed by computing Kaplan-Meier survival estimates for the "best" early improvement definition in comparison to non early improvement. Subgroup analyses were conducted to test whether the results were consistent across treatment subgroups.


RESULTS
48.8% of patients in our sample were remitters. The overall response rate was 79.6%. A 20% reduction of HAMD-21 total baseline score at Day 14 provided a sensitivity of 75% and a specificity of 59% for response prediction. This definition of early improvement was an even more sensitive predictor for remission (80%) with a limited specificity (43%). The AUC value of about 0.68 for early response (20% improvement) indicates good predictability for both time intervals tested (Day 14 and Day 28) and changed only marginally with increased percentages in score reduction (AUC=0.71 and 0.73, respectively). More than one third (37%) of all patients who had not improved at Day 14 showed not response in the later treatment course (this was the case for nearly half of all patients (43%) at Day 28). Similar results were obtained by Kaplan-Meier survival analyses. Log-rank test showed significantly longer time to response in patients with non-early improvement (p<0.0001).


CONCLUSIONS
Results were assessed by a post-hoc analysis based on prospectively collected data. Several caveats of a naturalistic design must be mentioned, especially there was no control group and only a limited number of stratification factors could be considered.


CONCLUSIONS
The results support earlier findings that early improvement in the first two weeks may predict with high sensitivity later response and remission, even in hospitalized patients suffering from a more severe degree of depression. Since we used a naturalistic study design, the data may be considered as a replication of previous results drawn from RCTs in a naturalistic environment. We found a global antidepressant effect which was consistent across treatment subgroups regarding sensitivity values. However, we are aware of the inability of effectiveness studies to draw causal treatment relationships from the uncontrolled approach. Nevertheless, the replication of previous results might indicate that a drug switch during treatment in case of lack of early improvement could be accelerated.
Henkel
Verena
V
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany.
Seemüller
Florian
F
Obermeier
Michael
M
Adli
Mazda
M
Bauer
Michael
M
Mundt
Christoph
C
Brieger
Peter
P
Laux
Gerhard
G
Bender
Wolfram
W
Heuser
Isabella
I
Zeiler
Joachim
J
Gaebel
Wolfgang
W
Mayr
Andreas
A
Möller
Hans-Jürgen
HJ
Riedel
Michael
M
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006801:Humans; D007297:Inpatients / Q000523:psychology / Q000706:statistics & numerical data; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011569:Psychiatric Status Rating Scales; D013997:Time Factors; D016896:Treatment Outcome
D000928:Antidepressive Agents